Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.

SecurityOME / Omega Protein Corp. (68210P107)
CEO and PresidentScholtes Bret
IndustryFats And Oils
Institutional Owners8
Institutional Shares2,349,299 - 10.45%
Common Shares Outstanding22,478,928 shares (as of 2017-09-30)
Institutional Value$ 52,099,000 USD

Institutional Stock Ownership and Shareholders()

OME / Omega Protein Corp. Institutional Ownership

Omega Protein Corp. (NYSE:OME) has 8 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,349,299 shares. Largest shareholders include Numeric Investors Llc, BlackRock Fund Advisors, BlackRock Institutional Trust Company, N.A., BlackRock Investment Management, LLC, Commonwealth Equity Services, Inc, BlackRock Advisors LLC, BlackRock Group LTD, and Kernodle & Katon Asset Management Group, LLC.
Omega Protein Corp. (NYSE:OME) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href=""><img src="" alt="OME / Omega Protein Corp. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Prev Value
Current Value
2017-02-10 13F-HR BlackRock Group LTD 13,537 6,654 -50.85 316 167 -47.15
2018-04-26 13F-HR SIMPLEX TRADING, LLC Call 111 0 -100.00 0 0
2018-02-14 13F-HR CORNERSTONE CAPITAL MANAGEMENT HOLDINGS LLC. 201,494 0 -100.00 3,354 0 -100.00
2017-08-14 13F-HR NUMERIC INVESTORS LLC 940,511 907,811 -3.48 18,857 16,250 -13.83
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 579,896 578,414 -0.26 13,552 14,489 6.91
2017-02-10 13F-HR BlackRock Fund Advisors 614,886 722,527 17.51 14,370 18,099 25.95
2017-02-10 13F-HR BlackRock Advisors LLC 11,944 11,645 -2.50 279 292 4.66
2018-02-16 13F-HR/A Commonwealth Equity Services, Inc 14,953 30,955 107.02 268 515 92.16
2018-02-14 13F-HR NUMERIC INVESTORS LLC 537,792 0 -100.00 8,954 0 -100.00
2017-01-13 13F-HR MetLife Securities, Inc 3 0 -100.00 0 0
2017-05-12 13F-HR Kernodle & Katon Asset Management Group, LLC 32 1
2017-02-10 13F-HR BlackRock Investment Management, LLC 92,511 91,261 -1.35 2,162 2,286 5.74

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 68210P107